市場調查報告書
商品編碼
1123201
醫藥品受託製造的全球市場(2022年~2028年)Global Pharmaceutical Contract Manufacturing Market Research and Forecast 2022-2028 |
全球醫藥品受託製造的市場規模,在預測期間內預計以約6.9%的年複合成長率成長。對已證明在滿足法規要求方面非常有效的尖端流程和生產技術的需求日益成長,成為促進製藥產業的CMO的成長的最重要要素。
本報告提供全球醫藥品受託製造市場相關調查分析,市場區隔分析,地區分析,預測,企業簡介等資訊。
Global Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis by Category (Human-Based Drugs and Animals Based Drugs), By Type (Sterile Manufacturing and Non-Sterile Manufacturing,), by Product (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation and Others) and by services (Manufacturing Services, Non-Clinical Services, and Research & Development) Forecast, 2021-2027
The global market for pharmaceutical contract manufacturing is projected to have a considerable CAGR of around 6.9% during the forecast period. All pharmaceutical companies operate as outsourcing companies, dealing with the development and manufacturing of drugs, which leads to business scalability and revenue, which allows for the development of new drugs. The growing need for state-of-the-art processes and production technologies, which have proven highly effective in meeting regulatory requirements, is the most important factor driving the growth of CMOs in the pharmaceutical industry. The increasing number of cell therapy candidates, combined with their steady growth through the various stages of clinical development and their complicated manufacturing process, drives up demand for manufacturing services for these therapies. Therefore, this factor creates an opportunity for market growth. However, the dynamic changes seen in this sector, combined with extreme margin pressure, are expected to restrict growth significantly.
Impact of COVID-19 on global pharmaceutical contract manufacturing market
The recent COVID-19 pandemic has increased demand for pharmaceuticals and sparked the growth of vaccines, antiviral vaccines, antibody therapy, and other pharmaceutical products. Contract development and manufacturing organizations are growing as a result of the pandemic, as many larger manufacturing units hire contract development and manufacturing organizations for pharmaceutical drug development and production. Although many pharmaceutical companies, research institutes and contract research organizations, collaborate to turn research findings into effective pharmaceutical products. For instance, Thermo Fisher Scientific Inc. (U.S.) partnered with INOVIO Pharmaceuticals, Inc. (U.S.) in September 2020 to manufacture and commercialize INOVIO's DNA COVID-19 vaccine candidate INO-4800. This collaboration will enable Thermo Fisher Scientific Inc to meet emerging demand for a COVID-19 vaccine that is both effective and safe.
Segmental Outlook
The global pharmaceutical contract manufacturing market is segmented based on category, type, product and service. Based on the category the market is further classified into human-based drugs and animals-based drugs. On the basis of type, the market is further segregated into sterile manufacturing and non-sterile manufacturing. Further on the basis of product, the market is classified into over-the-counter (OTC) drugs, active pharmaceutical ingredients (API), finished dosage formulation and others (nutritional products and packaging) and based on services the market is segmented into manufacturing services, non-clinical services, and research & development.
Global Pharmaceutical Contract Manufacturing Market Share by Products, 2020(%)
Global Pharmaceutical Contract Manufacturing Market Share by Products
Global Pharmaceutical Contract Manufacturing Market to be driven by active pharmaceutical ingredients (API)
Among products, the active pharmaceutical ingredients (API), the segment is projected to hold a considerable share in the market owing to factors such as the rising prevalence of chronic diseases including cardiovascular diseases and cancer and increasing advancements in active pharmaceutical ingredient (API) manufacturing. The API segment is experiencing significant changes as a result of the supply chain disruption caused by COVID-19. Due to geopolitical situations and the desire to reduce dependence on China for API products, countries such as India are being preferred over China for API export. Furthermore, pharmaceutical firms benefit from API production outsourcing because it eliminates the need for costly manufacturing unit installation and labor force. However, unfavorable drug pricing policies in various countries, as well as high manufacturing costs, are expected to restrain the segment growth.
Regional Outlook
Geographically, the global pharmaceutical contract manufacturing market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Europe is projected to grow at a significant CAGR during the forecast period. The market growth is attributed due to the region's large number of clinical trials, large API production base, modern manufacturing capabilities, the existence of leading pharmaceutical companies, and expansion in the generics market. The key players operating in the region are Aenova Group, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent Inc., Famar S.A. among others.
Global Pharmaceutical Contract Manufacturing Market Growth, by Region 2021-2027
Global Pharmaceutical Contract Manufacturing Market Growth, by Region
North America to hold a considerable share in the global Pharmaceutical Contract Manufacturing market
Geographically, North America is projected to hold a significant market share in the global pharmaceutical contract manufacturing market. This expansion is being fueled by an increase in the number of companies outsourcing projects in this region's developing economies. Additionally, because of rising healthcare costs, the US has a substantial market share in the pharmaceutical contract manufacturing sector. Furthermore, the rise in the prevalence of chronic conditions such as diabetes and cancer has increased the demand for injectable drug delivery in the US fueling the growth of the pharmaceutical contract manufacturing market.
Market Players Outlook
The key players in the pharmaceutical contract manufacturing market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Baxter International Inc, Pfizer Inc., Boehringer Ingelheim International GmbH., Amgen Inc., among others. These market players adopt various strategies such as product launches, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. In January 2021, Novartis International AG announced that it has signed an initial agreement to use its manufacturing capacity and capabilities to combat the COVID-19 pandemic by assisting in the manufacturing of the Pfizer-BioNTech COVID-19 Vaccine. Novartis will use its sterile manufacturing facilities at its Stein, Switzerland, site under the terms of the agreement. With this expansion, the company will use its manufacturing capabilities to support the global supply of COVID-19 vaccines and therapeutics.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global Pharmaceutical Contract Manufacturing market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.